EP Patent

EP2594277A1 — Tablet containing ferric citrate

Assigned to Japan Tobacco Inc · Expires 2013-05-22 · 13y expired

What this patent protects

The present invention provides a new preparation which is a tablet containing (1) ferric citrate, (2) a polyvinyl alcohol-polyethylene glycol graft copolymer, and (3) a polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer.

USPTO Abstract

The present invention provides a new preparation which is a tablet containing (1) ferric citrate, (2) a polyvinyl alcohol-polyethylene glycol graft copolymer, and (3) a polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer.

Drugs covered by this patent

Auryxia (FERRIC CITRATE) · Keryx Biopharms

Patent Metadata

Patent number: EP2594277A1
Jurisdiction: EP
Classification: —
Expires: 2013-05-22
Drug substance claim: No
Drug product claim: No
Assignee: Japan Tobacco Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.